Tobam Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Tobam cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 62.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 11,784 shares of the biopharmaceutical company’s stock after selling 19,683 shares during the period. Tobam’s holdings in Alnylam Pharmaceuticals were worth $2,773,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $61,160,000. Strategic Financial Concepts LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $41,529,000. Eventide Asset Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after acquiring an additional 137,333 shares during the period. Los Angeles Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares during the last quarter. Finally, Telemark Asset Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $27,503,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,964 shares of company stock worth $20,622,925. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research reports. Raymond James raised their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Barclays upped their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Finally, Bank of America lifted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $278.25 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm’s fifty day moving average is $252.31 and its 200 day moving average is $261.81. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.